Which Hormones and Contraception for Women with APS? Exogenous Hormone Use in Women with APS - Current Rheumatology Reports
- ️Sammaritano, Lisa R.
- ️Fri Apr 30 2021
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
•• Sammaritano LR, Bermas BL, Chakravarty E, Chambers C, Clowse ME, Lockshin MD, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Care Res. 2020;72(4):461–88 This guideline presents recommendations regarding contraception, fertility preservation, assisted reproductive technology, pregnancy assessment and management, hormone replacement therapy and medication use before, during and after pregnancy. The recommendations are directed towards patients with any rheumatic disease, but specific recommendations are provided for patients with SLE, APS and anti-Ro and La antibodies where relevant.
Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera RH, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295–306.
Schwartz EB, Manzi S. Risk of unintended pregnancy among women with systemic lupus erythematosus. Arthritis Rheum. 2008;59(6):863–6.
Yazdany J, Trupin L, Kaiser R, et al. Contraceptive counseling and use among women with systemic lupus: a gap in health care quality? Arthritis Care Res. 2011;63(3):358–65.
Birru Talabi M, Clowse ME, Blalock SJ, Moreland L, Siripong N, Borrero S. Contraception use among reproductive-age women with rheumatic diseases. Arthritis Care Res. 2019;71(8):1132–40.
Mendel A, Bernatsky S, Pineau CA, St-Pierre Y, Hanly JG, Urowitz MB, et al. Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. Rheumatol. 2019;58(7):1259–67.
DeNoble AE, Hall KS, Xu X, Zochowski MK, Piehl K, Dalton VK. Receipt of prescription contraception by commercially insured women with chronic medical conditions. Obstet Gynecol. 2014;123(6):1213–20.
Champaloux SW, Tepper NK, Curtis KM, Zapata LB, Whiteman MK, Marchbanks PA, et al. Contraceptive use among women with medical conditions in a nationwide privately insured population. Obstet Gynecol. 2015;126(6):1151–9.
Trussell J. Contraceptive failure in the United States. Contraception. 2011;83(5):397–404.
Amy JJ, Tripathi V. Contraception for women: an evidence-based overview. Br Med J. 2009;339(7):b2895.
Winner B, Peipert JF, Zhao Q, Buckel C, Madden T, Allsworth JE, et al. Effectiveness of long-acting reversible contraception. N Engl J Med. 2012;366:1998–2007.
Kavanaugh ML, Pliskin E. Use of contraception among reproductive-aged women in the United States, 2014 and 2016. F S Rep. 2020;1(2):83–93.
Kestelman P, Trussell J. Efficacy of the simultaneous use of condoms and spermicides. Fam Plan Perspect. 1991;23:226–7.
Khialani D, Rosendaal F, van Hylckama Vlieg A. Hormonal contraceptives and the risk of venous thrombosis. In: Seminars in thrombosis and hemostasis. 2020. https://doi.org/10.1055/s-0040-1715793.
Dore DD, Normal H, Loughlin J, Seeger JD. Extended case-control study results on thromboembolic outcomes among transdermal contraceptive users. Contraception. 2010;81:408–13.
Biswas J, Mann M, Webberley H. Oral contraception. Obstet Gynaecol Reprod Med. 2008;18(12):317–23.
Hidalgo M, Bahamondes L, Perrotti M, Diaz J, Dantas-Monteiro C, Petta C. Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years. Contraception. 2002;65(2):129–32.
World Health Organization, editor. Medical eligibility criteria for contraceptive use. 5th ed: World Health Organization; 2015. https://www.who.int/reproductivehealth/publications/family_planning/Ex-Summ-MEC-5/en/
Moreno V, Bosch FX, Muñoz N, Meijer CJ, Shah KV, Walboomers JM, et al. International Agency for Research on Cancer (IARC) Multicentric Cervical Cancer Study Group. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet. 2002;359:1085–92.
Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet. 1996;347:1713–27.
Stam-Slob MC, Lambalk CB, van de Ree MA. Contraceptive and hormonal treatment options for women with history of venous thromboembolism. BMJ. 2015;351:h4847.
Van Hylckama VA, Helmerhorst FM, Vandenbroucke JP, Doggen CJM, Rosendaal FR. The venous thromboembolic risk of oral contraceptives, effects of oestrogen dose and progestin type: results of the MEGA case-control study. Brit Med J. 2009;339:b2921.
Khialani D, Le Cessie S, Lijfering WM, Cannegieter SC, Rosendaal FR, van Hylckama Vlieg A. The joint effect of genetic risk factors and different types of combined oral contraceptives on venous thrombosis risk. Br J Hematol. 2020. https://doi.org/10.1111/bjh.16666.
Abdollahi M, Cushman M, Rosendaal FR. Obesity: risk of venous thrombosis and the interaction of coagulation factor levels and oral contraceptives. Thromb Haemost. 2003;89:493–8.
Pettiti DB, Sidney S, Bernstein A, Wolf S, Quesenberry C, Ziel HK. Stroke in users of low dose contraceptives. N Engl J Med. 1996;335:8–15.
Kemmeren JM, Tanis BC, van den Bosch MA, Bollen EL, Helmerhorst FL, van der Graf Y, et al. Risk of arterial thrombosis in relation to oral contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke. Stroke. 2002;33:1202–8.
Hennessy S, Berlin JA, Kinman JL, Margolis DJ, Marcus SM, Strom BL. Risk of venous thromboembolism from oral contraceptives containing gestodene and desogestrel versus levonorgestrel: a meta-analysis and formal sensitivity analysis. Contraception. 2001;64:125–33.
World Health Organization. Cardiovascular disease and use of oral and injectable progesterone-only contraceptives and combined injectable contraceptives. Results of an international multicenter case-control study. Contraception. 1998;57(5):315–24.
Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, Zapata LB, et al. US medical eligibility criteria for contraceptive use, 2016. Morb Mortal Wkly Rep Recomm Rep. 2016;65(3):1–103.
Mantha S, Karp R, Raghavan V, et al. Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis. BMJ. 2012;345:e4944.
Van Hylckama VA, Helmerhort FM, Rosendaal FR. The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or levonorgestrel intrauterine device. Arterioscler Thromb Vasc Biol. 2010;30:2297–300.
Bergendal A, Persson I, Odeberg J, Sundström A, Holmström M, Schulman S, et al. Association of venous thromboembolism with hormonal contraception and thrombophilic genotypes. Obstet Gynecol. 2014;124:600–9.
Glisic M, Shahzad S, Tsoli S, Chadni M, Asllanaj E, Rojas LZ, et al. Association between progestin-only contraceptive use and cardiometabolic outcomes: a systematic review and meta-analysis. Eur J Prev Cardiol. 2018;25(10):1042–52.
Vaillant-Roussel H, Ouchchane L, Dauphin C, Philippe P, Ruivard M. Risk factors for recurrence of venous thromboembolism associated with the use of oral contraceptives. Contraception. 2011;84(5):e23–30.
Le Moigne E, Tromeur C, Delluc A, Gouillou M, Alavi Z, Lacut K, et al. Risk of recurrent venous thromboembolism on progestin-only contraception: cohort study. Haematologica. 2016;101(1):e12–4.
Floyd JL, Beasely AD, Swaim LS, Turrentine MA, Nijjar JB. Association of immediate postpartum etonorgestrel implant insertion and venous thromboembolism. Obstet Gynecol. 2020;135(6):1275–80.
Darney P, Patel A, Rosen K, Shapiro LS, Kaunitz AM. Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials. Fertil Steril. 2009;91(5):1646–53.
Haider Z, D'Souza R. Non–contraceptive benefits and risks of contraception. Best Pract Res Clin Obstet Gynaecol. 2009;23(2):249–62.
Hubacher D, Lopez L, Steiner MJ, Dorfinger L. Menstrual pattern changes from levonorgestrel subdermal implants and DMPA: a systematic review and evidence-based comparisons. Contraception. 2009;80:113–8.
American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. ACOG Comm opinion number 415: depo-medroxyprogesterone acetate and bone effects. Obstet Gynecol. 2008;12:727–30.
Lyus R, Lohr P, Prager S. Use of the Mirena LNG-IUS and Paragard CuT380A intrauterine devices in nulliparous women. Contraception. 2010;81(5):367–71.
Stringer EM, Kaseba C, Levy J, Sinkala M, Goldenberg RL, Chi BH, et al. A randomized trial of the intrauterine device versus hormonal contraception in women who are infected with the human immunodeficiency virus. Am J Obstet Gynecol. 2007;197(2):144-e1–.e8.
Huguelet PS, Sheehan C, Spitzer RF, Scott S. Use of the levonorgestrel 52-mg intrauterine system in adolescent and young adult solid organ transplant recipients: a case series. Contraception. 2017;95(4):378–81.
Zerner J, Doil KL, Drewry J, Leeber DA. Intrauterine contraceptive device failures in renal transplant patients. J Reprod Med. 1981;26(2):99–102.
Danowski A, de Azevedo MNL, Petrie M. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. J Rheumatol. 2009;36(6):1195–9.
Erkan D, Harrison MJ, Levy R, Peterson M, Petri M, Sammaritano L, et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody–positive individuals. Arthritis Rheum. 2007;56(7):2382–91.
Brouwer JL, Bijl M, Veeger NJ, Kluin-Nelemans HC, van der Meer J, et al. The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus. Blood. 2004;104:143–8.
Girolami A, Zanon E, Zanardi S, Saracino MA, Simioni P. Thromboembolic disease developing during oral contraceptive therapy in young females with antiphospholipid antibodies. Blood Coagul Fibrinolysis. 1996;7:497–501.
Bacci S, Urquiola G, del Medico P, Sanabria JA, Bacci JC, Guzman M, et al. Budd-Chiari syndrome, pulmonary thromboembolism, and deep venous thrombosis associated with the “lupus anticoagulant” and recent use of oral contraceptives. Gen. 1990;44(3):237–42.
Urbanus RT, Siegerink B, Roest M, Rosendaal FR, de Groot PG, Algra A. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol. 2009;8(11):998–1005.
Asherson RA, Harris NE, Gharavi AE, Hughes GRV. Systemic lupus erythematosus, antiphospholipid antibodies, chorea and oral contraceptives. Arthritis Rheum. 1986;29:1535–6.
Islander MK, Khan M. Chorea as the initial presentation of oral contraceptive related systemic lupus erythematosus. J Rheumatol. 1989;16:850.
Yamakami LYS, de Araujo DB, Silva CA, Baracat EC, de Carvalho JF. Severe hemorrhagic corpus luteum complicating anticoagulation in antiphospholipid syndrome. Lupus. 2011;20:523–6.
Cretel E, Cacoub P, Le Thi HD, Gompel A, Amoura Z, Piette JC. Massive ovarian hemorrhage complicating oral anticoagulation in the antiphospholipid syndrome: a report of three cases. Lupus. 1999;8:482–5.
ACOG. Committee on Practice Bulletins – Gynecology ACOG practice bulletin number 73: use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol. 2006;107:1453–72.
Pisoni CN, Cuadrado MJ, Khamashta MA, Hunt BJ. Treatment of menorrhagia associated with oral anticoagulation: efficacy and safety of the levonorgestrel releasing intrauterine device (Mirena coil). Lupus. 2006;15(12):877–80.
Rebelo RC, Pignaton E, Bahamondes MV, Costallat LT, Appenzeller S, Bahamondes L, et al. Disease activity and thromboembolic events in women with systemic lupus erythematosus with and without anti-phospholipid syndrome: users of the 52-mg levonorgestrel-releasing intrauterine system. Arch Gynecol Obstet. 2019;299(6):1597–605.
van Vlijmen EF, Veeger NJ, Middeldorp S, Hamulyák K, Prins MH, Büller HR, et al. Thrombotic risk during oral contraceptive use and pregnancy in women with factor V Leiden or prothrombin mutation: a rational approach to contraception. Blood. 2011;118(8):2055–61.
• Klok FA, Barco S. Optimal management of hormonal contraceptives after an episode of venous thromboembolism. Thromb Res. 2019;181S1:S1–5 This paper reviews contraception efficacy and safety for patients with history of venous thromboembolism, and evaluates relative risk of various hormonal contraceptives.
Martinelli I, Lensing AW, Middeldorp S, Levi M, Beyer-Westendorf J, Van Bellen B, et al. Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. Blood. 2016;127(11):1417–25.
The North American Menopause society. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017;24(7):728–53.
The U.S. Preventive Services Task Force. Hormone therapy for the prevention of chronic conditions in post-menopausal women: recommendations from the U.S. preventive services task force. Ann Intern Med.2005;142(10):855.
Beral V. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet (London, England). 2003;362(9382):419–27.
Cushman M. Estrogen plus progestin and risk of venous thrombosis. JAMA. 2004;292(13):1573.
Marjoribanks J, Farquhar C, Roberts H, Lethaby A. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2012;7. https://doi.org/10.1002/14651858.CD004143.pub4.
Smith NL. Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. JAMA. 2004;292(13):1581.
Sweetland S, Beral V, Balkwill A, Liu B, Benson VS, Canonico M, et al. Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study. J Thromb Haemost. 2012;10(11):2277–86.
Straczek C, Oger E, Yon de Jonage-Canonico MB, Plu-Bureau G, Conard J, Meyer G, et al. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women. Circulation. 2005;112(22):3495–500.
Rosendaal FR, Vessey M, Rumley A, Daly E, Woodward M, Helmerhorst FM, et al. Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis. Br J Haematol. 2002;116(4):851–4.
Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Lévesque H, et al. Hormone therapy and venous thromboembolism among postmenopausal women. Circulation. 2007;115(7):840–5.
Rovinski D, Ramos RB, Fighera TM, Casanova GK, Spritzer PM. Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: a systematic review and meta-analysis. Thromb Res. 2018;168:83–95.
Canonico M, Plu-Bureau G, Lowe GDO, Scarabin P-Y. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ. 2008;336(7655):1227–31.
• Pinkerton JV, James AH. Management of menopausal symptoms for women who are at high risk of thrombosis. Clin Obstet Gynecol. 2018;61(2):260–8 This review offers options for alleviation of menopausal symptoms in women with increased risk for venous thromboembolism.
Krause MS, Nakajima ST. Hormonal and nonhormonal treatment of vasomotor symptoms. Obstet Gynecol Clin. 2015;42(1):163–79.
Nelson HD, Vesco KK, Haney E, Fu R, Nedrow A, Miller J, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA. 2006;295(17):2057–71.
Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause 2013; 20:888–902.
Bhupathiraju SN, Grodstein F, Stampfer MJ, Willett WC, Crandall CJ, Shifren J, et al. Vaginal estrogen use and chronic disease risk in the Nurses’ Health Study. Menopause. 2018;26(6):603.
de Melo AS, dos Reis RM, Ferriani RA, Vieira CS. Hormonal contraception in women with polycystic ovary syndrome: choices, challenges, and noncontraceptive benefits. Open Access J Contracept. 2017;8:13.
Vercellini P, Buggio L, Frattaruolo MP, Borghi A, Dridi D, Somigliana E. Medical treatment of endometriosis-related pain. Best practice & research. Clin Obstet Gynaecol. 2018;51:68–91.
Yuk JS, Song JY, Lee JH, Park WI, Ahn HS, Kim HJ. Levonorgestrel-releasing intrauterine systems versus oral cyclic medroxyprogesterone acetate in endometrial hyperplasia therapy: a meta-analysis. Ann Surg Oncol. 2017;24(5):1322–9.
Grandone E, Di Micco PP, Villani M, Colaizzo D, Fernández-Capitán C, Del Toro J, et al. Venous thromboembolism in women undergoing assisted reproductive technologies: data from the RIETE registry. Thromb Haemost. 2018;118(11):1962–8.
•• Machin N, Pagni MV. Review: hormones and thrombosis: risk across the reproductive years and beyond. Transl Res. 2020;225:9–19 This is a comprehensive review of endogenous and exogenous hormone therapies for a spectrum of reproductive health issues, with suggestions for limiting thrombosis in at-risk patients.
Xu X, Chlebowski RT, Shi J, Barac A, Haque R. Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors. Breast Cancer Res Treat. 2019;174(3):785–94.
Getahun D, Nash R, Flanders WD, Baird TC, Becerra-Culqui TA, Cromwell L, et al. Cross-sex hormones and acute cardiovascular events in transgender persons: a cohort study. Ann Intern Med. 2018;169(4):205–13.
Goldstein Z, Khan M, Reisman T, Safer JD. Managing the risk of venous thromboembolism in transgender adults undergoing hormone therapy. J Blood Med. 2019;10:209–16.
Manikkuttiyil C, Nguyen H. Megestrol. [Updated 2020 Jun 25]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK559205
Poulter NR, Chang CL, Farley TM, Meirik O. Risk of cardiovascular diseases associated with oral progestagen preparations with therapeutic indications. Lancet. 1999;354(9190):1610.